Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers SquibbThe Motley Fool • 07/14/26
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire • 07/13/26
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)The Motley Fool • 07/07/26
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.The Motley Fool • 07/06/26
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating IncomesSeeking Alpha • 07/03/26
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/01/26
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 06/29/26
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to NoteZacks Investment Research • 06/23/26
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026Business Wire • 06/18/26
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer DrugBenzinga • 06/17/26
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb24/7 Wall Street • 06/15/26
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.The Motley Fool • 06/11/26